[KH explains] Why Korea has been so quick to adopt ‘global minimum tax’
Mass walkout by trainee doctors nears deadline as health services crippled
Teachers and native English instructors now required to undergo drug testing
[Today’s K-pop] Karina of aespa is dating actor Lee Jae-wook: report
Russia sending North Korea food in return for arms: Seoul defense chief
Yoon says 2,000 increase in med school quota non-negotiable
Legality issues linger as nurses fill treatment void Tuesday
Why Cha Eun-woo’s name keeps popping up in politics
University ranking hierarchy leads to wage gap later in life: study
Ultrafine dust levels this year could be severe: ministry
Daewoong, Zydus ink $92m deal to develop generic drug in USBy Shim Woo-hyun
Published : Dec. 11, 2023 - 18:21
Daewoong Pharmaceutical announced Monday that the company has signed an exclusive licensing agreement with Zydus Worldwide DMCC to co-develop leuprolide acetate for depot suspension, DWJ108U, a generic of AbbVie’s prostate cancer, endometriosis and uterine fibroids treatment, Lupron Depot.
Based in the UAE, Zydus Worldwide DMCC is a wholly-owned subsidiary of Zydus Lifesciences, which was also formerly known as Cadila Healthcare Limited.
“Together with Zydus, Daewoong Pharmaceutical will aim to develop and commercialize a generic of AbbVie’s Lupron Depot in the US market,” an official from Daewoong Pharmaceutical said.
The value of the licensing contract between the two companies is estimated at around $92.4 million, including $25.5 million in a commercialization milestone payment, and an additional $66.9 million upon the new treatment's potential US launch.
The total amount is equivalent to 9.6 percent of Daewoong’s annual sales last year.
According to clinical research firm IQVIA’s data, leuprolide acetate for depot suspension had annual sales of approximately $671 million in the US with a growth rate of 10 percent in 2023.
Under the agreement, Daewoong will be responsible for the preclinical studies, production and supply of DWJ108U. The company said it will produce DWJ108U at its manufacturing facilities located in Osong, North Chungcheong Province.
Zydus, on the other hand, will take full charge of clinical trials and commercialization of DWJ108U in the US market.
“Given the complexity, complex generic drug products like Lupron Depot do not exist to date, and we aim to be the first company to manufacture the generic version of this complex, long-acting injectable Lupron Depot product,” Daewoong Pharmaceutical CEO Jeon Seng-ho said.
Managing Director of Zydus Lifesciences Sharvil Patel also said, “Enabling access to affordable generic versions for patients in the US has been our ongoing commitment. This is an important milestone and we are happy to work with Daewoong for the generic version of Lupron Depot.”
[Herald Interview] Rival heir to Kim Ju-ae unlikely to appear: unification minister
Coupang reports first profitable year
Main opposition wrestles with exodus over nomination spat